Incidence of Guillain-Barré Syndrome (GBS) in Latin America and the Caribbean before and during the 2015-2016 Zika virus epidemic: A systematic review and meta-analysis.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
04
03
2019
accepted:
10
07
2019
revised:
06
09
2019
pubmed:
27
8
2019
medline:
14
1
2020
entrez:
27
8
2019
Statut:
epublish
Résumé
A severe neurological disorder, Guillain-Barré syndrome (GBS) is the leading cause of acute flaccid paralysis. Enhanced surveillance of GBS in Latin America and the Caribbean (LAC) following the 2015-2016 Zika virus (ZIKV) epidemic presents an opportunity to estimate, for the first time, the regional incidence of GBS. For this systematic review and meta-analysis, we searched nine scientific databases and grey literature from January 1, 1980 to October 1, 2018. Sources with primary data on incident GBS cases in LAC within a well-defined population and timeframe, published in English, Spanish, Portuguese, or French, were included. We calculated the annual GBS incidence rates (IRs) and 95% confidence intervals (CIs) for each source based on published data. Following an assessment of heterogeneity, we used random-effects meta-analysis to calculate the pooled annual IR of GBS. The study is registered with PROSPERO, number CRD42018086659. Of the 6568 initial citation hits, 31 were eligible for inclusion. Background annual GBS IRs in Latin America ranged from 0.40 in Brazil to 2.12/100,000 in Chile. The pooled annual IR in the Caribbean was 1.64 (95% CI 1.29-2.12, I2<0.01, p = 0.44). During the ZIKV epidemic, GBS IRs ranged from 0.62 in Mexico to 9.35/100,000 in Martinique. GBS increased 2.6 (95% CI 2.3-2.9) times during ZIKV and 1.9 (95% CI 1.1-3.4) times during chikungunya outbreaks over background rates. A limitation of this review is that the studies included employed different methodologies to find and ascertain cases of GBS, which could contribute to IR heterogeneity. In addition, it is important to consider that data on GBS are lacking for many countries in the region. Background IRs of GBS appear to peak during arboviral disease outbreaks. The current review contributes to an understanding of the epidemiology of GBS in the LAC region, which can inform healthcare system planning and preparedness, particularly during arboviral epidemics. Registered with PROSPERO: CRD42018086659.
Sections du résumé
BACKGROUND
A severe neurological disorder, Guillain-Barré syndrome (GBS) is the leading cause of acute flaccid paralysis. Enhanced surveillance of GBS in Latin America and the Caribbean (LAC) following the 2015-2016 Zika virus (ZIKV) epidemic presents an opportunity to estimate, for the first time, the regional incidence of GBS.
METHODS AND FINDINGS
For this systematic review and meta-analysis, we searched nine scientific databases and grey literature from January 1, 1980 to October 1, 2018. Sources with primary data on incident GBS cases in LAC within a well-defined population and timeframe, published in English, Spanish, Portuguese, or French, were included. We calculated the annual GBS incidence rates (IRs) and 95% confidence intervals (CIs) for each source based on published data. Following an assessment of heterogeneity, we used random-effects meta-analysis to calculate the pooled annual IR of GBS. The study is registered with PROSPERO, number CRD42018086659. Of the 6568 initial citation hits, 31 were eligible for inclusion. Background annual GBS IRs in Latin America ranged from 0.40 in Brazil to 2.12/100,000 in Chile. The pooled annual IR in the Caribbean was 1.64 (95% CI 1.29-2.12, I2<0.01, p = 0.44). During the ZIKV epidemic, GBS IRs ranged from 0.62 in Mexico to 9.35/100,000 in Martinique. GBS increased 2.6 (95% CI 2.3-2.9) times during ZIKV and 1.9 (95% CI 1.1-3.4) times during chikungunya outbreaks over background rates. A limitation of this review is that the studies included employed different methodologies to find and ascertain cases of GBS, which could contribute to IR heterogeneity. In addition, it is important to consider that data on GBS are lacking for many countries in the region.
CONCLUSIONS
Background IRs of GBS appear to peak during arboviral disease outbreaks. The current review contributes to an understanding of the epidemiology of GBS in the LAC region, which can inform healthcare system planning and preparedness, particularly during arboviral epidemics.
TRIAL REGISTRATION
Registered with PROSPERO: CRD42018086659.
Identifiants
pubmed: 31449532
doi: 10.1371/journal.pntd.0007622
pii: PNTD-D-19-00307
pmc: PMC6730933
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007622Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Peripher Nerv Syst. 2017 Jun;22(2):68-76
pubmed: 28406555
JAMA Neurol. 2018 Sep 1;75(9):1089-1097
pubmed: 29799940
Paediatr Perinat Epidemiol. 2017 Nov;31(6):537-545
pubmed: 28806479
Lancet Infect Dis. 2017 Mar;17(3):e101-e106
pubmed: 28011234
J Neurol Sci. 2014 Sep 15;344(1-2):60-2
pubmed: 24993467
Lancet. 1997 Jan 4;349(9044):14-6
pubmed: 8988116
Epidemiol Serv Saude. 2018 Jun 28;27(2):e2017039
pubmed: 29995102
Am J Trop Med Hyg. 2018 Feb;98(2):586-588
pubmed: 29313470
Arq Neuropsiquiatr. 2016 Nov;74(11):937-943
pubmed: 27901259
J Travel Med. 2016 Sep 13;23(6):
pubmed: 27625400
PLoS One. 2017 Oct 3;12(10):e0185689
pubmed: 28973011
Emerg Infect Dis. 2016 Aug;22(8):1438-44
pubmed: 27144515
Neurology. 2001 Jun 12;56(11):1467-72
pubmed: 11402102
J Travel Med. 2019 Jun 11;26(5):
pubmed: 30753689
J Peripher Nerv Syst. 2017 Jun;22(2):121-126
pubmed: 28447405
Arq Neuropsiquiatr. 2004 Mar;62(1):33-7
pubmed: 15122430
J Infect Dis. 2010 Mar;201(5):746-50
pubmed: 20102270
Clin Infect Dis. 2014 Apr;58(8):1149-55
pubmed: 24415636
Glob Health Action. 2017;10(1):1398485
pubmed: 29235414
J Travel Med. 2018 May 1;25(suppl_1):S16-S26
pubmed: 29718435
Neuroepidemiology. 2009;32(2):150-63
pubmed: 19088488
J Neurol Sci. 2017 Jun 15;377:102-106
pubmed: 28477675
J Neurol Sci. 2014 Aug 15;343(1-2):221-3
pubmed: 24950899
J Travel Med. 2018 Jan 1;25(1):
pubmed: 29394382
Rev Med Inst Mex Seguro Soc. 2015 Nov-Dec;53(6):678-85
pubmed: 26506483
Neurology. 2010 Oct 19;75(16):1439-47
pubmed: 20861454
PLoS Negl Trop Dis. 2017 Aug 30;11(8):e0005869
pubmed: 28854206
Acta Neurol Scand. 2012 Jan;125(1):47-53
pubmed: 21428966
Am J Trop Med Hyg. 2016 Jun 1;94(6):1380-4
pubmed: 27022152
J Neurol. 2006 Feb;253(2):214-8
pubmed: 16096809
BMC Med. 2018 Oct 3;16(1):180
pubmed: 30285863
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Arq Neuropsiquiatr. 2002 Jun;60(2-B):367-73
pubmed: 12131933
J Travel Med. 2018 Jul 1;25(1):
pubmed: 30016469
J Travel Med. 2018 Aug 1;25(1):
pubmed: 30113689
N Engl J Med. 2016 Oct 20;375(16):1598-1601
pubmed: 27579558
J Clin Epidemiol. 2012 Sep;65(9):934-9
pubmed: 22742910
Neurol Sci. 2002 Sep;23(3):113-7
pubmed: 12391495
Am J Trop Med Hyg. 2017 Aug;97(2):356-360
pubmed: 28722564
EPI Newsl. 1994 Jun;16(3):1-2
pubmed: 12345536
Int J Infect Dis. 2016 Oct;51:133-134
pubmed: 27637419
Neurology. 2013 Apr 30;80(18):1650-4
pubmed: 23576619
PLoS Med. 2017 Jan 3;14(1):e1002203
pubmed: 28045901
J Travel Med. 2018 Jan 1;25(1):
pubmed: 30476232
Lancet. 2016 Apr 9;387(10027):1531-1539
pubmed: 26948433
J Neurol Sci. 2017 Oct 15;381:272-277
pubmed: 28991697
J Travel Med. 2016 Feb 29;23(3):
pubmed: 26929156
J Travel Med. 2016 Mar;23(3):
pubmed: 27356308
PLoS Negl Trop Dis. 2018 Feb 12;12(2):e0006212
pubmed: 29432457
Neuroepidemiology. 2011;36(2):123-33
pubmed: 21422765
J Infect Dis. 1997 Feb;175 Suppl 1:S160-4
pubmed: 9203710
Clin Infect Dis. 2017 Oct 16;65(9):1462-1468
pubmed: 29020245
Cell Stem Cell. 2016 May 5;18(5):587-90
pubmed: 26952870
J Autoimmun. 2017 Feb;77:123-138
pubmed: 28062188
J Peripher Nerv Syst. 2016 Dec;21(4):339-344
pubmed: 27477441
Pract Neurol. 2018 Aug;18(4):271-277
pubmed: 29618586
Neurology. 2008 Jul 1;71(1):21-7
pubmed: 18591502
Ann Neurol. 1994 Dec;36(6):859-63
pubmed: 7998771
J Infect Dis. 1997 Feb;175 Suppl 1:S37-42
pubmed: 9203690
Nat Rev Neurol. 2014 Aug;10(8):469-82
pubmed: 25023340
Lancet. 2016 Aug 13;388(10045):717-27
pubmed: 26948435
Lancet Neurol. 2013 Sep;12(9):906-919
pubmed: 23948177
J Epidemiol Community Health. 2013 Nov 1;67(11):974-8
pubmed: 23963506
J Travel Med. 2018 Jan 1;25(1):
pubmed: 29669058
J Child Neurol. 2003 Nov;18(11):741-7
pubmed: 14696900
J Peripher Nerv Syst. 2014 Mar;19(1):24-35
pubmed: 24456426
J Travel Med. 2017 May 1;24(3):
pubmed: 28355620
J Travel Med. 2018 May 1;25(suppl_1):S3-S9
pubmed: 29718434
Science. 2016 Jul 22;353(6297):353-4
pubmed: 27417493
Emerg Infect Dis. 2016 Nov;22(11):1894-1899
pubmed: 27603576